PART Act
Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.
Pharmaceutical Accountability, Responsibility, and Transparency Act or the PART Act
This bill expands requirements for manufacturers of certain drugs and medical devices to report information to the Food and Drug Administration (FDA) and contains related provisions.
A manufacturer of a life-saving drug or medical device must notify the FDA of certain issues that may affect the drug or device's availability, such as an increase in demand that the manufacturer is likely unable to meet or an export restriction imposed by a foreign country where the drug or device is being manufactured. The manufacturer must notify the FDA within five days of becoming aware of the issue.
The bill also expands the types of foreign manufacturers of drugs and medical devices that must register with the FDA. Additionally, the bill expands a requirement for registered manufacturers to submit periodic reports to the FDA by (1) increasing the frequency of such reports, and (2) requiring the reports to include additional information about the amounts of drugs and medical devices being manufactured.
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- Introduced in Senate Formatted Text PDF Formatted XML
Cite this page
U.S. Congress. (2026). S. 3781: PART Act. 116th Congress. Open America. https://openamerica.io/bill/116-S-3781/
"S. 3781: PART Act." 116th Congress, 2026, Open America, https://openamerica.io/bill/116-S-3781/.
S. 3781, 116th Cong. (2026), https://openamerica.io/bill/116-S-3781/.
[S. 3781: PART Act](https://openamerica.io/bill/116-S-3781/)